Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
Expires | Type | Strike | OI | Change | Percent |
---|---|---|---|---|---|
06/20/2025 | PUT | $40.00 | 9,514 | +3,575 | +60.20% |
06/20/2025 | PUT | $45.00 | 10,222 | +2,769 | +37.15% |
06/20/2025 | CALL | $55.00 | 4,558 | +837 | +22.49% |
06/18/2026 | CALL | $55.00 | 1,184 | +799 | +207.53% |
06/20/2025 | CALL | $50.00 | 7,919 | +367 | +4.86% |
08/15/2025 | PUT | $45.00 | 5,867 | +231 | +4.10% |
05/02/2025 | CALL | $52.00 | 200 | -24 | -10.71% |
05/02/2025 | PUT | $49.00 | 216 | -24 | -10.00% |
05/02/2025 | PUT | $47.00 | 314 | -27 | -7.92% |
05/16/2025 | CALL | $65.00 | 13,517 | -37 | -0.27% |
09/19/2025 | CALL | $52.50 | 1,768 | -40 | -2.21% |
08/15/2025 | PUT | $50.00 | 1,694 | -52 | -2.98% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
Name | Pct Held | Shares | Total |
---|---|---|---|
Vanguard Total Stock Market Index Fund | 3.07% | 64.63M | 4.03B |
Vanguard 500 Index Fund | 2.34% | 49.15M | 3.06B |
Fidelity 500 Index Fund | 1.11% | 23.31M | 1.45B |
SPDR S&P 500 ETF Trust | 1.09% | 23.02M | 1.43B |
iShares Core S&P 500 ETF | 0.90% | 18.98M | 1.18B |
Vanguard Index-Value Index Fund | 0.87% | 18.37M | 1.14B |
JP Morgan Equity Income Fund | 0.82% | 17.35M | 1.08B |
Select Sector SPDR Fund-Health Care | 0.82% | 17.27M | 1.08B |
American Mutual Fund Inc | 0.78% | 16.49M | 1.03B |
Vanguard Institutional Index Fund-Institutional Index Fund | 0.71% | 14.9M | 927.91M |
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months
05/02 03:37 pm
Benzinga
Read moreThis High-Yield Pharma Stock Looks Like an Incredible Bargain
04/30 06:45 am
The Motley Fool
Read moreAnalysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - Merck, Roche, Bristol-Myers Squibb Company, Johnson & Johnson Services, and AstraZeneca Dominate
04/30 04:56 am
GlobeNewswire Inc.
Read more4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
04/26 06:05 pm
The Motley Fool
Read moreBristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact
04/24 11:55 am
Benzinga
Read moreThermo Fisher Beats Q1 Estimates, Lowers Full-Year Forecast As Tariffs And Costs Take A Toll
04/23 04:49 pm
Benzinga
Read moreIs High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill?
04/15 07:39 am
The Motley Fool
Read moreThese Large-Cap Stocks With China And EU Exposure Got Crushed In The One Of The Most Volatile Trading Week (Apr 7-Apr 11): Are These In Your Portfolio?
04/13 11:33 am
Benzinga
Read moreSpecialists Set Sights on CLE Pipeline as Unmet Needs Persist and Candidate Pool Expands, According to Spherix Global Insights
04/10 01:58 pm
GlobeNewswire Inc.
Read moreBiopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline
04/10 05:59 am
GlobeNewswire Inc.
Read moreIs Vertex Pharmaceuticals Stock a Buy?
04/08 09:45 am
The Motley Fool
Read moreMinimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide
04/08 04:48 am
GlobeNewswire Inc.
Read moreMPYS Protein Stimulants Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape
04/07 01:00 pm
GlobeNewswire Inc.
Read moreIs Bristol Myers Squibb's High-Yielding Dividend Safe?
04/02 05:40 am
The Motley Fool
Read moreTumor-infiltrating Lymphocyte (TIL) Therapies Global Market Report 2025: 75+ Therapies are Under Development and 100+ Clinical Trials are Underway Globally
04/01 02:44 pm
GlobeNewswire Inc.
Read moreBeat the S&P 500 With This Cash-Gushing Dividend Stock
04/01 08:00 am
The Motley Fool
Read moreWhy Pfizer Is My Largest Healthcare Position
03/27 06:45 am
The Motley Fool
Read morePharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
03/21 12:31 pm
Benzinga
Read more5 Reasons the Schwab U.S. Dividend Equity ETF Is a Long-Term Buy for 2030 and Beyond
03/17 07:45 am
The Motley Fool
Read morePerspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
03/17 07:00 am
GlobeNewswire Inc.
Read more3 Stocks to Buy Amid Market Correction Triggered by Trump's Trade War
03/14 07:40 am
Investing.com
Read moreBristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
03/11 10:17 am
Benzinga
Read moreBristol Myers Unveils Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis
03/10 12:54 pm
Benzinga
Read moreGlobal Prostate Cancer Market to Reach USD 29.2 Billion by 2035, Driven by Aging Population and Awareness | Future Market Insights, Inc.
03/09 08:30 pm
GlobeNewswire Inc.
Read moreAcetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
03/06 02:00 pm
GlobeNewswire Inc.
Read moreCancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection
03/06 05:55 am
GlobeNewswire Inc.
Read moreAdvanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
03/03 02:00 pm
GlobeNewswire Inc.
Read moreInternational Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month
03/01 09:45 am
GlobeNewswire Inc.
Read moreGot $200? 2 Healthcare Stocks to Buy and Hold Forever
02/26 05:32 am
The Motley Fool
Read moreTALTZ’s Rapid Market Ascent Reflects its Unparalleled Ability to Transform the Treatment Landscape for Autoimmune Diseases | DelveInsight
02/24 02:00 pm
GlobeNewswire Inc.
Read moreBristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review
02/24 01:24 pm
Benzinga
Read moreQuestex’s Fierce Pharma Unveils the Conference Program for the Inaugural Fierce Pharma Engage, Over 100 Speakers Confirmed to Deliver Unparalleled Education
02/24 11:00 am
GlobeNewswire Inc.
Read moreCAPLYTA’s Strong Market Adoption Propels Its Rise as a Leading Antipsychotic Therapy | DelveInsight
02/21 02:00 pm
GlobeNewswire Inc.
Read moreHyperlipidemia Drugs Market Size to Promote USD 31.49 Bn by 2034
02/21 11:00 am
GlobeNewswire Inc.
Read moreBESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment
02/20 02:00 pm
GlobeNewswire Inc.
Read moreBristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer
02/19 05:14 pm
Benzinga
Read moreGlobal Immune Checkpoint Inhibitors Market to Cross USD 100 Billion by 2032 | DelveInsight
02/18 02:00 pm
GlobeNewswire Inc.
Read moreWant Decades of Passive Income? Buy This ETF and Hold It Forever.
02/18 07:15 am
The Motley Fool
Read more$536.73 Bn Organ Preservation Solution Market Strategies and Opportunities to 2033: New R&D Center to Revolutionize Organ Preservation Techniques and Enhance Global Healthcare Solutions
02/12 05:47 am
GlobeNewswire Inc.
Read moreBristol Myers Squibb Tops Q4 Estimates
02/06 10:55 am
The Motley Fool
Read moreBristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
02/06 10:08 am
Benzinga
Read more2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
02/03 09:32 am
The Motley Fool
Read moreGeorge Medicines appoints Amy Carroll as Senior Vice President of Medical Affairs
02/03 08:00 am
GlobeNewswire Inc.
Read more3 Cheap Dividend Stocks That Pay More Than Double the S&P 500 Average
01/29 05:40 am
The Motley Fool
Read moreBiological Drugs Strategic Research Report 2024-2030, Profiles of 45+ Players Including Abbott Laboratories, Amgen, Baxter, Biogen, BMS, Eli Lilly and Co, GSK, Merck, Novartis, and Pfizer
01/27 11:49 am
GlobeNewswire Inc.
Read moreMove Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
01/25 08:45 am
The Motley Fool
Read more7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - Synergistic Rise of Pumps, CGMs, and Ultra-rapid-acting Insulins in T1D Management
01/17 05:53 am
GlobeNewswire Inc.
Read moreLike Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
01/13 11:03 am
Benzinga
Read moreObesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
01/09 03:12 pm
Benzinga
Read moreNUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries
01/09 11:53 am
GlobeNewswire Inc.
Read more